Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Mar 05, 2021 3:30pm
177 Views
Post# 32730639

RE:RE:RE:RE:RE:JAMA Cardiology Study

RE:RE:RE:RE:RE:JAMA Cardiology Study
G1945V wrote: GB, ..... would you agree that if VMS 3.0 can detect Atrial Dysfunction it could very well detect inflammation of the heart muscle (myocarditis) that typically occurs in patients with advanced COVID-19 disease.
 

jmo
G1945V 


 


 

Clearly, myocarditis can be linked to dysfunction, and in turn heart failure.

 

The point is, not whether there is some indirect finding in a paediatric study that could be applied to Covid cardiac monitoring (which is in adults)...
 

If you want to study monitoring of the heart, in patients with Covid, you would design a study and do it -in COVID patients with cardiac disease.

 

Furthermore, if you deemed that VPTs instrument, and knowledge based reconstruction, could revolutionize this monitoring, why are we not reading about this from any cardiologists, and we are only making these indirect suppositions on a Internet stock board for a OTC stock on the TSX venture.

 

The Bottom line is that this technology is not being adopted yet, and certainly not being recommended and adopted to this point, to my knowledge.


If you can provide a reference, to a cardiology organization, or a hospital that is embracing this technology, please do so. Otherwise this is speculation, that is not based on facts.

 

Speculations are quite rampant on this board, including predictions of share price that could be one dollar, two dollars, three dollars, even $12, all of which without any  revenue basis, or mathematical support.


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse